Tyrosinemia

Liver Disease in Children, Third Edition

Volumn , Issue , 2007, Pages 694-713

  Mitchell, Grant ^a   Russo, Pierre A ^b   Dubois, Josée ^a   Alvarez, Fernando ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77958143678     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511547409.031     Document Type: Chapter

References (117)

1. Medes G. A new error of tyrosine metabolism: tyrosinosis. The intermediary metabolism of tyrosine and phenylalanine. Biochem J 1932;26:917–40.
2. Baber MD. A case of congenital cirrhosis of the liver with renal tubular defects akin to those in the Fanconi syndrome. Arch Dis Child 1956;31:335–9.
3. Sakai K, Kitagawa T. An atypical case of tyrosinosis (1- parahydroxyphenyllactic aciduria). Part 1. Clinical and laboratory findings. Jikei Med J 1957;2:1–10.
4. Sakai K, Kitagawa T. An atypical case of tyrosinosis (1-parahydroxyphenyllactic aciduria). Part 2. A research on the metabolic block. Jikei Med J 1957;2:11–15.
5. Sakai K, Kitagawa T, Yoshioka K. An atypical case of tyrosinosis (1-parahydroxyphenyllactic aciduria). Part 3. The outcome of the patient; pathological and biochemical observations of the organ tissues. Jikei Med J 1959;6:15–24.
6. Larochelle J, Privé L, Bélanger M, et al. Hereditary tyrosinemia. I. Clinical and biological study of 62 cases. Pediatrie 1973;28:5–18.
7. Paradis K, Weber A, Seidman EG, et al. Liver transplantation for hereditary tyrosinemia: the Quebec experience. Am J Hum Genet 1990;47:338–42.
8. Kvittingen EA. Hereditary tyrosinemia type I –an overview. Scand J Clin Lab Invest Suppl 1986;184:27–34.
9. Mieles LA, Esquivel CO, Van Thiel DH, et al. Liver transplantation for tyrosinemia. A review of 10 cases from the University of Pittsburgh. Dig Dis Sci 1990;35:153–7.
10. Van Thiel DH, Gartner LM, Thorp FK, et al. Resolution of the clinical features of tyrosinemia following orthotopic liver transplantation for hepatoma. J Hepatol 1986;3:42–8.
11. van Spronsen FJ, Berger R, Smit GP, et al. Tyrosinaemia type I: orthotopic liver transplantation as the only definitive answer to a metabolic as well as an oncological problem. J Inherit Metab Dis 1989;12(suppl 2):339–42.
12. Lindblad B, Lindstedt S, Steen G. On the enzymic defects in hereditary tyrosinemia. Proc Natl Acad Sci U S A 1977; 74:4641–5.
13. Kvittingen EA, Jellum E, Stokke O. Assay of fumarylacetoacetate fumarylhydrolase in human liver-deficient activity in a case of hereditary tyrosinemia. Clin Chim Acta 1981; 115:311–19.
14. Berger R, Smit GP, Stoker-de Vries SA, et al. Deficiency of fumarylacetoacetase in a patientwith hereditary tyrosinemia. Clin Chim Acta 1981;114:37–44.
15. Gray RG, Patrick AD, Preston FE, et al. Acute hereditary tyrosinaemia type I: clinical, biochemical and haematological studies in twins. J Inherit Metab Dis 1981;4:37–40.
16. Phaneuf D, Labelle Y, Bérubé D, et al. Cloning and expression of the c DNA encoding human fumarylacetoacetate hydrolase, the enzyme deficient in hereditary tyrosinemia: assignment of the gene to chromosome 15. Am J Hum Genet 1991; 48:525–35.
17. Kvittingen EA, Brodtkorb E. The pre- and post-natal diagnosis of tyrosinemia type I and the detection of the carrier state by assay of fumarylacetoacetase. Scand J Clin Lab Invest Suppl 1986;184:35–40.
18. Russo P, O’Regan S. Visceral pathology of hereditary tyrosinemia type I. Am J Hum Genet 1990;47:317–24.
19. Worthen HG. Renal toxicity of maleic acid in the rat. Lab Invest 1963;12:791–801.
20. Stoner E, Starkman H, Wellner D, et al. Biochemical studies of a patient with hereditary hepatorenal tyrosinemia: evidence of glutathione deficiency. Pediatr Res 1984;18:1332–6.
21. Meister A, Larsson A. Glutathione synthetase deficiency and other disorders of the gamma-glutamyl cycle. In: Scriver CR, Beaudet AL, Sly WS, et al., eds. The metabolic basis of inherited disease. New York: Mc Graw-Hill, 1989:855–68.
22. Jorquera R, Tanquay RM. The mutagenicity of the tyrosine metabolite, fumarylacetoacetate, is enhanced by glutathione depletion. Biochem Biophys Res Commun 1997;232: 42–8.
23. Kvittingen EA, Rootwelt H, Brandtzaeg P, et al. Hereditary tyrosinemia type I: self-induced correction of the fumarylacetoacetase defect. J Clin Invest 1993;91:1816–21.
24. Kvittingen EA, Rootwelt H, Berger R, et al. Self-induced correction of the geneticdefect in tyrosinemia type I. JClin Invest 1994;94:1657–61.
25. Ahmad S, Teckman JH, Lueder GT. Corneal opacities associated with NTBC treatment. Am J Ophthalmol 2002;134: 266–8.
26. Niswander L, Kelsey G, Schedl A, et al. Molecular mapping of albino deletions associated with early embryonic lethality in the mouse. Genomics 1991;9:162–9.
27. Grompe M, al-Dhalimy M, Ou CN, et al. Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. Genes Dev 1993;7:2298–307.
28. Al Dhalimy M, Overturf K, Finegold M, et al. Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I. Mol Genet Metab 2002;75:38–45.
29. Endo F, Kubo S, Awata H, et al. Complete rescue of lethal albino c14Co S mice by null mutation of 4-hydroxyphenylpyruvate dioxygenase and induction of apoptosis of hepatocytes in these mice by in vivo retrieval of the tyrosine catabolic pathway. J Biol Chem 1997;272:24426–32.
30. Kubo S, Sun M, Miyahara M, et al. Hepatocyte injury in tyrosinemia type I is induced by fumarylacetoacetate and is inhibited by caspase inhibitors. Proc Natl Acad Sci U S A 1998;95:9552–7.
31. Grisham JW. Interspecies comparison of liver carcinogenesis: implications for cancer risk assessment. Carcinogenesis 1997;18:59–81.
32. Mitchell GA, Larochelle J, Lambert M, et al. Neurologic crises in hereditary tyrosinemia. N Engl J Med 1990;322:432–7.
33. Kappas A, Sassa S, Galbraith R. The porphyrias. In: Scriver CR, Beaudet AL, Sly WS, et al., eds. The metabolic basis of inherited disease. New York: Mc Graw-Hill, 1989:1305–66.
34. Strife CF, Zuroweste EL, Emmett EA, et al. Tyrosinemia with acute intermittent porphyria: aminolevulinic acid dehydratase deficiency related to elevated urinary aminolevulinic acid levels. J Pediatr 1977;90:400–4.
35. Rank JM, Pascual-Leone A, Payne W, et al. Hematin therapy for the neurologic crisis of tyrosinemia. J Pediatr 1991;118:136–9.
36. Manowski Z, Silver MM, Roberts EA, et al. Liver cell dysplasia and early liver transplantation in hereditary tyrosinemia. Mod Pathol 1990;3:694–701.
37. De Braekeleer M, Larochelle J. Genetic epidemiology of hereditary tyrosinemia in Quebec and in Saguenay-Lac-St- Jean. Am J Hum Genet 1990;47:302–7.
38. Bouchard G, Laberge C, Scriver CR. Hereditary tyrosinemia and vitamin-dependent rickets in Saguenay. A genetic and demographic approach [in French]. Union Med Can 1985;114:633–6.
39. Mitchell GA, Grompe M, Lambert M, Tanguay RM. Hypertyrosinemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. New York: Mc Graw Hill, 2001: 1777–806.
40. Grompe M, St-Louis M, Demers SI, et al. A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I. N Engl JMed 1994;331:353–7.
41. Poudrier J, St-Louis M, Lettre F, et al. Frequency of the IVS12+5G-A splice mutation of the fumarylacetoacetate hydrolase gene in carriers of hereditary tyrosinaemia in the French-Canadian population of Saguenay-Lac-St-Jean. Prenat Diagn 1996;16:59–64.
42. Ploos van Amstel JK, Bergman AJ, van Beurden EA, et al. Hereditary tyrosinemia type 1: novel missense, nonsense and splice consensus mutations in the human fumarylacetoacetate hydrolase gene; variability of the genotype-phenotype relationship. Hum Genet 1996;97:51–9.
43. St-Louis M, Leclerc B, Laine J, et al. Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I. Hum Mol Genet 1994;3:69–72.
44. Rootwelt H, Hoie K, Berger R, et al. Fumarylacetoacetate mutations in tyrosinaemia type I. Hum Mutat 1996;7:239–43.
45. Rootwelt H, Berger R, Gray G, et al. Novel splice, missense, and nonsense mutations in the fumarylacetoacetase gene causing tyrosinemia type 1. Am J Hum Genet 1994;55: 653–8.
46. Kvittingen EA, Borresen AL, Stokke O, et al. Deficiency of fumarylacetoacetase without hereditary tyrosinemia. Clin Genet 1985;27:550–4.
47. Gentz J, Johansson S, Lindblad B, et al. Excretion of deltaaminolevulinic acid in hereditary tyrosinemia. Clin Chim Acta 1969;23:257–63.
48. Croffie JM, Gupta SK, Chong SK, et al. Tyrosinemia type 1 should be suspected in infants with severe coagulopathy even in the absence of other signs of liver failure. Pediatrics 1999;103:675–8.
49. de Almeida IT, Leandro PP, Silva MF, et al. Tyrosinaemia type I with normal levels of plasma tyrosine. J Inherit Metab Dis 1990;13:305–7.
50. Grenier A, Lescault A, Laberge C, et al. Detection of succinylacetone and the use of its measurement in mass screening for hereditary tyrosinemia. Clin Chim Acta 1982;123: 93–9.
51. Haagen AAM, Duran M. Absence of increased succinylacetone in the urine of a child with hereditary tyrosinaemia type I. J Inherit Metab Dis 1987;10(suppl 2):323–5.
52. Laberge C, Grenier A, Valet JP, et al. Fumarylacetoacetase measurement as a mass-screening procedure for hereditary tyrosinemia type I. Am J Hum Genet 1990;47:325–8.
53. Jakobs C, Stellaard F, Kvittingen EA, et al. First-trimester prenatal diagnosis of tyrosinemia type I by amniotic fluid succinylacetone determination [letter]. Prenat Diagn 1990; 10:133–4.
54. Segal S. Disorders of galactose metabolism. In: Scriver CR, Beaudet AL, Sly WS, et al., eds. The metabolic basis of inherited disease. New York: Mc Graw-Hill, 1989:453–80.
55. Gitzelman R, Steinmann B, Van Der Berghe G. Disorders of fructose metabolism. In: Scriver CR, Beaudet AL, Sly WS, et al., eds. The metabolic basis of inherited disease. New York: Mc Graw-Hill, 1989:556–62.
56. Danks DM. Disorders of copper transport. In: Scriver CR, Beaudet AL, Sly WS, et al., eds. The metabolic basis of inherited disease. New York: Mc Graw-Hill, 1989:1411–32.
57. Chen YT, Coleman RA, Scheinman JI. Renal disease in type 1 glycogen storage disease. N Engl J Med 1988;318:7–11.
58. Nyhan WL. Abnormalities in amino acid metabolism in clinical medicine. Norwalk, CT:Appleton-Century-Crofts, 1984.
59. Berger R, Michals K, Galbraeth J, et al. Tyrosinemia type Ib caused by maleylacetoacetate isomerase deficiency: a new enzyme defect [abstract]. Pediatr Res 1988;23:328.
60. Fernandez-Canon JM, Baetscher MW, Finegold M, et al. Maleylacetoacetate isomerase (MAAI/GSTZ)-deficient mice reveal a glutathione-dependentnonenzymaticbypass in tyrosine catabolism. Mol Cell Biol 2002;22:4943–51.
61. Evans DI, Sardharwalla IB. Coagulation defect of congenital tyrosinaemia. Arch Dis Child 1984;59:1088–90.
62. Gentz J, Jagenburg R, Zetterstr¨om R. Tyrosinemia: an inborn error of tyrosine metabolism with cirrhosis of the liver and multiple renal tubular defects. J Pediatr 1965;66:670–96.
63. Ferrell LD, Crawford JM, Dhillon AP, et al. Proposal for standardized criteria for the diagnosis of benign, borderline, and malignant hepatocellular lesions arising in chronic advanced liver disease. Am J Surg Pathol 1993;17:1113–23.
64. Weinberg AG, Mize CE, Worthen HG. The occurrence of hepatoma in the chronic form of hereditary tyrosinemia. J Pediatr 1976;88:434–8.
65. Dionisi-Vici C, Boglino C, Marcellini M, et al. Tyrosinemia type I with early metastatic hepatocellular carcinoma: combined treatment with NTBC, chemotherapy and surgical mass removal. J Inherit Metab Dis 1997;20(suppl 1):3.
66. Cole DEC, Tithecott GA, Crocker JFS, et al. Alphaxalone/ alphadolone and porphyria. Lancet 1984;1:690.
67. Paradis K, Mitchell GA, Russo P. Tyrosinemia. In: Suchy FJ, ed. Liver disease in children. St. Louis: CVMosby, 1994:803–18.
68. Kvittingen EA, Talseth T, Halvorsen S, et al. Renal failure in adult patients with hereditary tyrosinaemia type I. J Inherit Metab Dis 1991;14:53–62.
69. Halvorsen S. Dietary treatment of tyrosinosis. Am JDis Child 1967;113:38–40.
70. Kogut MD, Shaw KN, Donnell GN. Tyrosinosis. Am J Dis Child 1967;113:47–53.
71. Sass-Kortsak A, Ficici S, Paunier L, et al. Observations on treatment in patients with tyrosyluria. Can Med Assoc J 1967;97:1089–95.
72. Suzuki Y, Konda M, Imai I, et al. Effect of dietary treatment on the renal tubular function in a patient with hereditary tyrosinemia. Int J Pediatr Nephrol 1987;8:171–6.
73. Bendon PW, Hug G. Glycogen accumulation in the pars recta of the proximal tubule in Fanconi syndrome. Pediatr Pathol 1986;6:411–29.
74. Parington MW, Haust MD. A patient with tyrosinemia and hypermethioninemia. Can Med Assoc J 1967;97:1059–64.
75. Baumann U, Preece MA, Green A, et al. Hyperinsulinism in tyrosinaemia type I. J Inherit Metab Dis 2005;28:131–5.
76. Lindberg T, Nilsson KO, Jeppsson JO. Hereditary tyrosinaemia and diabetes mellitus. Acta Paediatr Scand 1979;68: 619–20.
77. Edwards MA, Green A, Colli A, et al. Tyrosinaemia type I and hypertrophic obstructive cardiomyopathy [letter]. Lancet 1987;1:1437–8.
78. Lindblad B, Fällström SP, Höyer S, et al. Cardiomyopathy in fumarylacetoacetase deficiency (hereditary tyrosinaemia): a new feature of the disease. J Inherit Metab Dis 1987;10:319–22.
79. Andre N, Roquelaure B, Jubin V, Ovaert C. Successful treatment of severe cardiomyopathy with NTBC in a child with tyrosinaemia type I. J Inherit Metab Dis 2005;28:103–6.
80. Arora N, Stumper O, Wright J, et al. Cardiomyopathy in tyrosinaemia type I is common but usually benign. J Inherit Metab Dis 2006;29:54–7.
81. Dubois J, Garel L, Patriquin H, et al. Imaging features of type 1 hereditary tyrosinemia: a review of 30 patients. Pediatr Radiol 1996;26:845–51.
82. Crone J, Möslinger D, Bodamer OA, et al. Reversibility of cirrhotic regenerative liver nodules upon NTBC treatment in a child with tyrosinemia type 1. Acta Pediatr 2003;92: 625–8.
83. Privé L. Pathological findings in patients with tyrosinemia. Can Med Assoc J 1967;97:1054–6.
84. Carson NA, Biggart JD, Bittles AH, et al. Hereditary tyrosinaemia. Clinical, enzymatic, and pathological study of an infant with the acute form of the disease. Arch Dis Child 1976;51:106–13.
85. Halvorsen S, Pande H, Loken AC, et al. Tyrosinosis. A study of 6 cases. Arch Dis Child 1966;41:238–49.
86. Dehner LP, Snover DC, Sharp HL, et al. Hereditary tyrosinemia type I (chronic form): pathologic findings in the liver. Hum Pathol 1989;20:149–58.
87. Yu JS, Walker-Smith JA, Burnard ED. Neonatal hepatitis in premature infants simulating hereditary tyrosinosis. Arch Dis Child 1971;46:306–9.
88. Watanabe S, Okita K, Harada T. Morphologic studies of the liver cell dysplasia. Cancer 1983;51:2197–205.
89. Laberge C, Lescault A, Tanguay RM. Hereditary tyrosinemias (type I): a new vista on tyrosine toxicity and cancer. Adv Exp Med Biol 1986;206:209–21.
90. Tremblay M, Bélanger L, Larochelle J, et al. Hereditary tyrosinemia: examination of the liver by electron microscopy of hepatic biopsies: observation of 7 cases [in French]. Union Med Can 1977;106:1014–16.
91. Phillips MJ, Poucell S, Patterson J. The liver: an atlas and text of ultrastructural pathology. New York: Raven, 1987.
92. Jetvic MM, Thorp FK, Hruban Z. Hereditary tyrosinemia with hyperplasia of juxtaglomerular apparatus. Am J Clin Pathol 1974;61:423–37.
93. Tuchman M, Freese DK, Sharp HL, et al. Contribution of extrahepatic tissues to biochemical abnormalities in hereditary tyrosinemia type I: study of three patients after liver transplantation. J Pediatr 1987;110:399–403.
94. Flatmark A, Bergan A, Sodal G, et al. Does liver transplantation correct the metabolic defect in hereditary tyrosinemia? Transplant Proc 1986;18:67–8.
95. Callurel P, Feldman G, Prandi D. Immune complex type glomerulonephritis in cirrhosis of the liver. Am J Pathol 1975;80:329–36.
96. Perry TL. Tyrosinemia associated with hypermethioninemia and islet cell hyperplasia. Can Med Assoc J 1967;97:1067–75.
97. Jaffe R, Hashida Y, Yunis EJ. The endocrine pancreas of the neonate and infant. In: Rosenberg HS, Bernstein J, eds. Perspectives in pediatric pathology. Paris:Masson, 1980:137–66.
98. Hardwick DF, Dimmick JE. Metabolic cirrhoses of infancy and early childhood. In: Rosenberg HS, Bolande RP, eds. Perspectives in pediatric pathology. Chicago: Year Book, 1976:103–44.
99. Mitchell GA, Lambert M, Tanguay RM. Hypertyrosinemia. In: Scriver CR, Beaudet AL, Sly WS, et al., eds. The metabolic and molecular bases of inherited disease. New York:Mc Graw- Hill, 1995:1077–176.
100. Ameen VZ, Powell GK, Rassin DK. Cholestasis and hypermethioninemia during dietary management of hereditary tyrosinemia type 1. J Pediatr 1986;108:949–53.
101. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly W, et al., eds. The metabolic basis of inheriteddisease. New York:Mc Graw-Hill, 1989:693–741.
102. Freese DK, Tuchman M, Schwarzenberg SJ, et al. Early liver transplantation is indicated for tyrosinemia type I. J Pediatr Gastroenterol Nutr 1991;13:10–15.
103. Flye MW, Riely CA, Hainline BE, et al. The effects of early treatment of hereditary tyrosinemia type I in infancy by orthotopic liver transplantation. Transplantation 1990;49: 916–21.
104. Jehan P, Buchman M, Odièvre M. Dietary management of hereditary tyrosinemia. Apropos of 7 cases. Ann Pediatr (Paris) 1984;31:33–40.
105. Lindblad B. Treatment with glutathione and other sulfhydryl compounds in hereditary tyrosinemia. In: Larsson A, ed. Functions of glutathione: biochemical, physiological, toxicological, and clinical aspects. New York: Raven, 1983:337–46.
106. Herzog D, Martin S, Turpin S, Alvarez F. Normal glomerular filtration rate in long-term follow-up of children after orthotopic liver transplantation. Transplantation 2006;81: 672–7. 97a. Mc Diarmid SV, Ettenger RB, Fine RF. Serial decrease in glomerular filtration rate in long-term pediatric liver transplantation survivors treated with cyclosporine. Transplantation 1989;47:314–18.
107. Paradis K, O’Regan S, Seidman E. Improvement in true glomerular filtration rate after cyclosporine fractionation in pediatric liver transplant recipients. Transplantation 1991;51: 922–4.
108. Laine J, Salo MK, Krogerus L, et al. The nephropathy of type I tyrosinemia after liver transplantation. Pediatr Res 1995;37:640–5.
109. al Edreesi M, Caille G, Dupuis C, et al. Safety, tolerability, and pharmacokinetic actions of diltiazem in pediatric liver transplant recipients on cyclosporine. Liver Transplant Surg 1995;1:383–8.
110. Pierik LJ, van Spronsen FJ, Bijleveld CM, van Dael CM. Renal function in tyrosinaemia type I after liver transplantation: a long-term follow-up. J Inherit Metab Dis 2005;28:871–6.
111. Overturf K, Al-Dhalimy M, Ou CN, et al. Serial transplantation reveals the stem-cell-like regenerative potential of adult mouse hepatocytes. Am J Pathol 1997;151:1273–80.
112. Grompe M. Therapeutic liver repopulation for the treatment of metabolic liver diseases. Hum Cell 1999;12:171–80.
113. Lee LA. Advances in hepatocyte transplantation: a myth becomes reality. J Clin Invest 2001;108:367–9.
114. Wang X, Foster M, Al Dhalimy M, et al. The origin and liver repopulating capacity of murine oval cells. Proc Natl Acad Sci U S A 2003;100(suppl 1):11881–8.
115. Lock EA, Gaskin P, Ellis MK, et al. Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane-1, 3-dione (NTBC): effect on enzymes involved in tyrosine catabolism and relevance to ocular toxicity in the rat. Toxicol Appl Pharmacol 1996;141:439–47.
116. Magera MJ, Gunawardena ND, Hahn SH, et al. Quantitative determination of succinylacetone in dried blood spots for newborn screening of tyrosinemia type I. Mol Genet Metab 2006;88:16–21.
117. Allard P, Grenier A, Korson MS, et al. Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots. Clin Biochem 2004;37:1010–15.